幽门螺杆菌重组VacA-CtxB蛋白的原核表达及免疫原性研究
|
摘要
目的:构建H.pylori细胞空泡毒素(VacA)毒性片段与霍乱毒素B亚单位(CtxB)融合基因的原核表达载体,并诱导表达,以获得重组蛋白,鉴定其免疫原性,为制备防治H.pylori感染的口服疫苗奠定基础。
方法:
1)用PCR扩增出vacA目的基因片段,构建原核表达质粒pQE30-vacA。
2)用PCR扩增出ctxB目的基因片段,克隆至pQE30-vacA质粒vacA
的基因上游,构建含双基因的表达质粒pQE-vctB。
3) pQE-vctB转化E.coli DH5α,IPTG诱导表达重组蛋白VCTB,Western blotting分析抗原性,镍离子柱纯化。
4)重组蛋白VCTB口服免疫小鼠,ELISA检测小鼠血清特异性IgG、小肠冲洗液IgA,以鉴定其免疫原性。
结果:经测序vctB融合基因由1092bp组成,为编码364个氨基酸残基的多肽。重组蛋白VCTB经SDS-PAGE分析相对分子量(Mr)约为40KD,表达量占全菌的20%以上,亲和层析后可获得纯度为92%以上的蛋白。Western blotting分析显示能分别与VacA抗血清和CT抗血清反应。ELISA检测显示,免疫小鼠的血清特异性抗体IgG,肠粘液IgA显著高于VacA对照组(P<0.01 )。
结论:vacA和ctxB融合基因原核表达质粒构建成功,转化E.coli DH5α表达菌获得了重组蛋白VCTB,表达量较高,纯度较高,有良好的抗原性和免疫原性,口服免疫小鼠可明显提高其免疫效果,产生较高水平的IgA,可用于制备防治H.pylori感染的口服疫苗。
5 Objective: To construct and express the fusion gene of H.pylori vacA and cholera toxin subunit B (ctxB), To explore the immune response with the conjugated antigen of VacA-CtxB, which would lay a foundation for prophylaxis and therapy of H.pylori infection.
Methods: A recombinant strain which could express bivalent antigen of VacA and CtxB subunit was constructed.
1) vacA gene was amplified by PCR and cloned into plasmid pQE30which was plasmid pQE30-vacA.
2) ctxB gene was amplified by PCR and cloned into plasmid pQE30-vacA, which was plasmid pQE-vctB.
3) translated into E.coli strain DH5 a to express VCTB fusion protein. Its immunogenicity was analyzed by Western blotting.
4) After purification,to fedm ice by oral immunization. antibody(IgG and IgA) in the delected by ELISA assay.
Results: vctB fusion gene was sequenced as 1092bp, the fusion protein encoded polypeptides of 364 amino acid residues. The molecular weight was 40kD analysiced by SDS-PAGE.The levels of soluble expression product was about 20% of total cell protein.After affinity chromatography,the purity of fusion protein was above 92%.Western blotting analysis of confirmed that fusion protein could be specicifically recognized by the serum of anti-VacA and anti-CT. The specific antibody response in mice immunized with VCTB was determined by ELISA. The results showed that the levels of specific antibody were higher than those of controls.
Conclusion:The successful construction and expression fusion gene of Helicobacter pylori vacA and cholera toxin subunit B(ctxB). Experiment indicated that the oral immunization with VCTB induces effective mucosal immune responece and produced higher levels IgA. The recombinant fusion protein VCTB can be used as an effective oral vaccine for prevention infection of H.pylori.
方法:
1)用PCR扩增出vacA目的基因片段,构建原核表达质粒pQE30-vacA。
2)用PCR扩增出ctxB目的基因片段,克隆至pQE30-vacA质粒vacA
的基因上游,构建含双基因的表达质粒pQE-vctB。
3) pQE-vctB转化E.coli DH5α,IPTG诱导表达重组蛋白VCTB,Western blotting分析抗原性,镍离子柱纯化。
4)重组蛋白VCTB口服免疫小鼠,ELISA检测小鼠血清特异性IgG、小肠冲洗液IgA,以鉴定其免疫原性。
结果:经测序vctB融合基因由1092bp组成,为编码364个氨基酸残基的多肽。重组蛋白VCTB经SDS-PAGE分析相对分子量(Mr)约为40KD,表达量占全菌的20%以上,亲和层析后可获得纯度为92%以上的蛋白。Western blotting分析显示能分别与VacA抗血清和CT抗血清反应。ELISA检测显示,免疫小鼠的血清特异性抗体IgG,肠粘液IgA显著高于VacA对照组(P<0.01 )。
结论:vacA和ctxB融合基因原核表达质粒构建成功,转化E.coli DH5α表达菌获得了重组蛋白VCTB,表达量较高,纯度较高,有良好的抗原性和免疫原性,口服免疫小鼠可明显提高其免疫效果,产生较高水平的IgA,可用于制备防治H.pylori感染的口服疫苗。
5 Objective: To construct and express the fusion gene of H.pylori vacA and cholera toxin subunit B (ctxB), To explore the immune response with the conjugated antigen of VacA-CtxB, which would lay a foundation for prophylaxis and therapy of H.pylori infection.
Methods: A recombinant strain which could express bivalent antigen of VacA and CtxB subunit was constructed.
1) vacA gene was amplified by PCR and cloned into plasmid pQE30which was plasmid pQE30-vacA.
2) ctxB gene was amplified by PCR and cloned into plasmid pQE30-vacA, which was plasmid pQE-vctB.
3) translated into E.coli strain DH5 a to express VCTB fusion protein. Its immunogenicity was analyzed by Western blotting.
4) After purification,to fedm ice by oral immunization. antibody(IgG and IgA) in the delected by ELISA assay.
Results: vctB fusion gene was sequenced as 1092bp, the fusion protein encoded polypeptides of 364 amino acid residues. The molecular weight was 40kD analysiced by SDS-PAGE.The levels of soluble expression product was about 20% of total cell protein.After affinity chromatography,the purity of fusion protein was above 92%.Western blotting analysis of confirmed that fusion protein could be specicifically recognized by the serum of anti-VacA and anti-CT. The specific antibody response in mice immunized with VCTB was determined by ELISA. The results showed that the levels of specific antibody were higher than those of controls.
Conclusion:The successful construction and expression fusion gene of Helicobacter pylori vacA and cholera toxin subunit B(ctxB). Experiment indicated that the oral immunization with VCTB induces effective mucosal immune responece and produced higher levels IgA. The recombinant fusion protein VCTB can be used as an effective oral vaccine for prevention infection of H.pylori.
引文
[1] Vandenplas Y. Helicobacter pylori infection.World J Gastroenterol 2000; 6:20-31
[2] Yang Y, Deng CS, Yao XJ,et al. Effect of Helicobacter pylori on morphology and growth of gastric epithelial cells. Shijie Huaren Xiaohua Zazhi 2000; 8(5):500-504
[3] Liu HF,Liu WW,Fang DC,et al. Gastric epithelial apoptosis induced by Helicobacter pylori and its relationship with Bax protein expression. Shijie Huaren Xiaohua Zazhi 2000;8(8): 860-862
[4] Chen SY, Wang JY, Ji Y, et al. Effects of Helicobacter pylori and protein kinase C on gene mutation in gastric cancer and precancerous lesions. Shijie Huaren Xiaohua Zazhi 2001; 9(3): 302-307
[5] International agency for reseach on cancer. Schistosomes, liver fluker and Helicobacter Pylori.IARC monographs on the evalition on carcinogenic risks to human. Vo161, Lyon: IASC, 1994.
[6] Montenero AS, Mollichelli N,Zumbo F, et a1.Helicobacter pylori and atrial fibrillation:a possible pathogenic link.Heart,2005,91:960-961.
[7] ho S,Miyaji H,Azuma T,et a1.Hyperammonaemia and helicobacter pylori[J].Lancet,1995,346:124.
[8] 焦建中,赵春林,陈官培.慢性肝病中幽门螺杆菌感染的临床研究[J].中国综合临床,2003,19(1):47—48。
[9] Yamanishi S,Iizumi T'Watanad E,et a1.Implications for induction of autoimmunity via activation of B-1 ceNs by helicobacterpylofi urease.Infect Immun,2006,74:248-256。
[10] Pounder RE, Ng D. The prevalence of Helicobacter Pylori infection in different countries.science, 1995, 267:17.
[11] Guisset M,Coton T,Rey P,Debonne JM.Helicobacter pylori infection in developing countries.Med Trop(Mars),1997;57:77-82
[12] Weyermann,Maria;Adler,Guido;Brenner,Hermann;RothenbacherDietrich,The Mother as Source of Helicobacter pylori Infection,Epidemiology. 2006, 17(3):332-334
[13] Li Yy,Hu Pj,Du,GG.et al.The prevalence of Helicobacter pylori infection in P.R.China.Am J Gastroenterol,1991;86:446-449
[14] Czinn SJ. Nedrud JG. Oral immunization against Heli-cobacter pylori.Infect Immun,1991,59:2359-2363.
[15] Chen M,Lee A,Hazell S.Immunisation against gastrichelicobacter infection in a mouse/Helicobacter fel/smode1.Lancet,1992,339:1120～1121
[16] Kotloff K, Sztein M, Wasserman S, et al. Safety and immunogenicity of oral inactivated whole cell helicobacer pylori vaccine with adjuvant among volumteer with or without subclincalinfection. Infect Immun 2001,69(6):3581-3590
[17] [Suzuki H, Nomura S, Masaoka T, et al. Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther. 2004 Jul;20 Suppl 1:185-9
[18] Molinari M, Galli C, Norais N, et al. Vacuoles induced by Helicobacter pylori toxin contain both late endosomal and lysosomal markers. : J Biol Chem 1997 ,272(40): 25339-44.
[19] Tombola F,Carlesso C,Szabo I, et al.Helicobacter pylori vacuolating toxin forms anion-selective channels in planar lipidbilayers: possible implications for the mechanism of cellular vacuolation. Biophys J 1999, 76: 1401-1409.
[20] Pai R, Sasaki E,Tarnawski AS. Helicobacterpylori vacuolating cytotoxin (VacA) alters cytoskeleton-associated proteins and interferes with re-epithelialization of wounded gastric epithelial monolayers. Cell Biol Int. 2000; 24(5): 291-301.
[21] Weel JFL,Hulst RWP,Gerrits Y,et al.The interrelationship between cytotoxin-associated geneA,vaculating cytotoxin, and Helicobacter pylori related diseases. J Infect Dis,1996,173;1171-1175.
[22] 童明宏,孙晨光.幽门螺杆菌极其毒力因子和胃十二指肠疾病关系的研究.上海医学检验杂志,2000,17(2):96-99.
[23] Atanassov C, Pezennec L, d'Alayer J, et al. Novel antigens of Helicobacter pylori correspond to ulcer-related antibody pattern of sera from infected patients. J Clin Microbiol 2002 ,40(2):547-52.
[24] Ghiara P,Rossi M,Marchetti M, et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection[.Infect Immun,1997,65(12):4996-5002.
[25] Czerkinsky C, Russekk MW, Lycke, et al. Oral adminostration of a streptococal antigen coupled to cholera toxin B subunit evikes strong antibody in salivary glands and extramucosal tisses. Infect Immun, 1989,57(4):1072-1077
[26] Tamura S, Samegai Y, Kurata H, et al. Protection against Influenza virus infection by vaccine inocu lated intranasally with cholera toxin B subunit. Vaccine,1988, 6(5): 409-413
[27] Mckenzie S, Halsey J. Cholera toxin B subunit as a carrier protein to stimulated a mucosal immun response. J Immun,1984,133:1818-1824
[28] 李明峰,刘新梅,凌贞,等.幽门螺杆菌口服疫苗的研制及免疫原性研究.中华微生物学和免疫学杂志,2002,22(4)398-402
[29] Chikubo K,Isaka M,Yasuda Y et al.Recombinant cholera tixin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosallyco-adminnisterad bovine serum albumin. Vaccine, 1998; 16(1):150-155.
[30] Wu bong-ying, Russel M W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine, 1998; 16(2):286-292.
[31] F.奥斯伯 R.布伦特、R.E.金斯顿等编,颜子颖,王海林译,精编分子生物学实验指南,北京:科学出版社,1999 年, 39-40.
[32] F.奥斯伯 R.布伦特、R.E.金斯顿等编,颜子颖,王海林译,精编分子生物学实验指南,北京:科学出版社,1999 年,22-23.
[33] J.萨姆布鲁克, D.W.拉塞尔著,黄培堂等译,分子克险实验指南.[M],第 3 版,北京,科学出版社,2002,87-91
[34] J.萨姆布鲁克, D.W.拉塞尔著,黄培堂等译,分子克险实验指南.[M],第 3 版,北京,科学出版社,2002,91-98
[1] J.萨姆布鲁克, D.W.拉塞尔著,黄培堂等译,分子克险实验指南.[M],第 3 版,北京,科学出版社,2002,418-424
[2] J.萨姆布鲁克,E.F.弗里奇,T.曼尼阿蒂斯著,金冬雁,黎孟枫等译.[M]. 分子克隆实验指南,第 3 版,北京:科学出版社,2002 年,1252-1259.
[3] Gouy M, Gautier C. Codon usage in bacteria: correlation with geneexpressivity.Nucleic Acids Res. 1982, 10:7055-7074
[4] Gutman G A, Hatfield G W. Nonrandom utilization of codon pairs in Escherichia coli.Proc Natl Acad Sci USA. 1989, 86:3699-3703
[5] Cabilly S.Growth at sub-optimal temperatures allows the production of functional, antigen-binding Fab fragments in Escherichia coli.Gene. 1989 Dec 28;85(2):553-7.
[6] Fischer B,Summer I,Goodenough P.Isolation ,renaturation,and formation of disulfide bonds of eukaryotic proteins expressed in Escherichia coli as inclusion bodies.[J].Biotechnol Bioeng, 1993, 41(1): 3-13
[7] Rudolph R,Bohm G, lilie H, et al. Folding proteins. In: Creighton T E ed. Protein Function: A Practical Approach, 2nd.[J]. New York: IRL, 1997, 57-99
[8] CowleyDT, MackinRB. Expression, purification and charaterization of recombinant human proinsulin. [J].FEBS Lett, 1997, 402:124
[9] Kuruez I, Titus JA, Jost CA. Correct disulphide pairing and efficient refolding of detergent-solubilized single chain Fv proteins from bacterial inclusion bodies.[J]. Mol Immunol, 1995, 12:1443
[10] Patra AK,Mukhopadhyay R,Mukhija R,et al.Optimization of inclusion body solutilization and renaturation of recombinant human growth hormone from Escherichia coli.[J].Protein Expression Purif, 2000: 18: 182-19
[11] Creighton TE. How important is the molten globule for correct protein folding? Trends Biochem Sci, 1997, 22:6
[12] Maeda Y, Ueda T, Imoto T. Effective renaturation of denatured antibody improve its in vivo folding. [J].Protein Eng, 1995, 8:81-89
[13] Rozema D, Gellman S H. Artificial chaperone-assisted refolding of denatured- reduced lysizyme: modulation of the competition between renaturation and aggregation.[J]. Biochemistry, 1996, 35:15760-15771
[14] Sadana A.Protein refolding and inactivation during bioseparation: bioprocessing implications.[J].Biotech Bioeng, 1995, 48:481-489
[1] Sniezek PJ, Graham BC, Busch HB ,et al,Rapidly Growing Mycobacterial Infections After Pedicures,Arch dermatol 2003 May,139(5):629-634
[2] Prado, A. C., and Castillo, P. F. Lay clinics and an epidemic outbreak of mycobacterium skin and soft-tissue infection.,Plast Reconstr Surg. 2004 Feb;113(2):800-801.
[3] .Murillo J, Torres J, Bofill L, et al. Skin and wound infection by rapidly growing mycobacteria: an unexpected complication of liposuction and liposculpture. The Venezuelan Collaborative Infectious and Tropical Diseases Study Group.,Arch Dermatol. 2000 Nov;136(11):1347-1352.
[4] Villanueva A, Calderon RV, Vargas BA, et al.Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. Clin Infect Dis. 1997 Jun;24(6):1147-1153.
[5] Hofling-Lima AL, de Freitas D, Sampaio JL, et al. In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil.,Cornea. 2005 Aug;24(6):730-734.
[6] 刘军 李良成 扈庆华等,53株龟分枝杆菌脓肿亚种临床分离株的药敏试验研究.中国卫生检验杂志 2000, 10(4):407-408
[7] 杨致邦,陈清风,陈全等.龟分枝杆菌药物敏感性的及耐药性探讨,重庆医科大学学报,2001,26(3),247-249
[8] ISBN7-117-04066-1/R.4067 冯作化 医学分子生物学 人民卫生出版社
[9] Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis:1998 update. Tuber Lung Dis ,1998,79(1):3-29.
[10] Ahmad S, Mokaddas E, Fares E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolatesfrom Kuwait and Dubai. Diagn Microbiol Infect Dis,2002,44(3):245.
[11] Quan S, Venter H, Dabbs ER. Rivosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic.Antimicrob Agents Chemother,1997,41(11):2456-2460.
[12] 沙巍,翁心华,肖和平等。脓肿分支杆菌耐利福平情况及 rpoB 基因序列的研究 中华结核和呼吸杂志 2003,26(9)544-547
[13] Jamal MA, Maeda S, Nakata N,et al. Molecular basis of charithromycin-resistance in Mycobacterium avium intracellulare complex. Tuber Lung Dis. 2000;80(1):1-4..
[14] Wallace RJ jr, Meier A, brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium Chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother,1996 40(7):1676-1681.
[15] Vemulapalli RK, Cantey JR, Steed LL, et al. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection:case report and Literature review. J Infect,2001,43(3):163-168
[16] Pammananan T, Sander P, Brown BA, et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis, 1998,177(6):1573-1581.
[17] Zhao BY, Pine R, Domagala J,et al. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in hunan macrophages. Antimicrob Agents Chemother,1999,43(3):661-666.
[18] Isabelle G , Vincent J, Emmanuelle C.Correlation between Quinolone Susceptibility Patterns and Sequences in the A and B Subunits of DNA Gyrase in Mycobacteria. Antimicrob Agents Chemother. 1998 August; 42(8):2084–2088
[19] Isabelle G, Waladimir S, Emmanuelle C, et al. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum ,Microbiology, 1999; 145(9):2527-2532
1) Dea-Ayuela MA,Rama-Iniguez S,Bolas-Fernandez F.Vaccination of mice against intestinal Trichinella spiralis infections by oral administration of antigens microencapsulated in methacrilic acid copolymers.Vaccine,2006,24(15):2772-2780.
2) Hatzifoti C,Roussel Y,Harris AG,et a1.Mucosal immunization with a) a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.Helicobacter,2006,1 1(2):1 13-122.
3) Roelofs.Haarhuis K.Wu X.Gleichmann E.Oral tolerance to nickel requires CIM invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells.J Immunol,2004,173(2):1043-1050.
4) Talavera A,Ano G,Pino Y,et a1.Formulation in tablets of a cholera whole cells inactivated vaccine candidate.Vaccine,2006,24(16):338l-3387.
5) Karakasiliotis I,Paximadi E,Markoulatos P. Evolution of a rare vaccine-derived multirecombinant poliovirus.J Gen Virol,2005,86(Pt 11):3137-3142.
6) Franco MA, Angel J, Greenberg HB.Immunity and correlates of protectionfor rotavirus vaccines.Vaccine,2006,24(15):2718-2731.
7) Robert Putnak J,Coller BA,Voss G,et a1.An evaluation of dengue type-2 inactivated,recombinant subunit,and live-attenuated vaccine candidates in the rhesus macaque mode1.Vaccine,2005,23(35):4442-4452.
8) Sable SB,Verm a I,Khuller GK. Muhicomponent antitubemulous subunit vaccine based on immunodominan t antigens of Mycobacteriumtuberculosis.Vaccine 2005,23(32):4175-4184
9) Rouvio 0,Dvorkin T, Amir-Kmll H,et a1. Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of mufine cytomegalovirus in the salivary gland.Vaccine,2005,23(27):3508-3518.
10) 杨致邦,吴利先等。幽门螺杆菌 HpaA-CtxB 口服疫苗的研制及免疫原性研究. 中国免疫学杂志 2004,20(5)306-310
11) Lladser A.Parraga M,Quevedo L,et a1.Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.Immunobiology,2006,211(1-2):11-27.
12) Parida SK,Huygen K,Ryffel B,et a1. Novel Bacterial Delivery system with Attenuated Salmonella typhimurium Carrying Plasmid Encoding Mtb Antigen 85 Afor Mucosal Immunization:Establishment of Proof of Principle in TB Mouse Mode1.Ann N Y Acad Sci,2005,1056:366-378.
13) Dus Santos MJ, Carrillo C, Ardila F,et a1. Development of transgenlc alfalfa plants containing the fo t and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen.Vaccine,2005,23(15):1838-1843.
14) 14. Johnson DC, McFarland EJ, Muresan P, et a1. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborus and infants of HIV-1 infected women.J Infect Dis,2005,192(12):2129-2133.
15) Bellier B,Dalba C, Clem B,et a1. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant.Vaccine,2006,24(14):2643-2655.
16) Singh P,Destito G,Schneemann A,et a1.Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology.2006,4:2.
17) Faisant N,Akiki J,Siepmann F,et a1.Efects ofthe type of release medium on drug release from PLGA-based microparticles:Experiment and theory.Int J Pharm ,2006,314(2):189-197.
18) Mollenkopf HJ,Dietrich G,Fensterle J,et a1.Enhanced protective eficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles.Vaccine,2004,22(21-22):2690-2695.
19) Stanford M,Whittall T,Bergmeier LA,et a1.Oral tolerization with peptide
336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease.Clin Exp Immunol,2004,137(1):201-208.
20) Maier M.Seabrook TJ.Lemere CA.Medulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL),cholera toxin B subunit(CTB) and E.coli enterotoxin LT(R192G).Vaccine,2oo5,23(44):5 149-5159.
21) Helgeby A,Robson NC,Donachie AM ,et a1.The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity toincorporated antigens by specific targeting of B cells.J Immunol,2006,176(6):3697-3706.
22) Payette PJ,Ma X,Weeratna RD,et a1.Testing of CpG-optimized protein and DNA vaccines against the hepatitis B vinls in chimpanzees for immunogenicity and protection from hallenge.Intervirology,2006,49(3):144-151.
[2] Yang Y, Deng CS, Yao XJ,et al. Effect of Helicobacter pylori on morphology and growth of gastric epithelial cells. Shijie Huaren Xiaohua Zazhi 2000; 8(5):500-504
[3] Liu HF,Liu WW,Fang DC,et al. Gastric epithelial apoptosis induced by Helicobacter pylori and its relationship with Bax protein expression. Shijie Huaren Xiaohua Zazhi 2000;8(8): 860-862
[4] Chen SY, Wang JY, Ji Y, et al. Effects of Helicobacter pylori and protein kinase C on gene mutation in gastric cancer and precancerous lesions. Shijie Huaren Xiaohua Zazhi 2001; 9(3): 302-307
[5] International agency for reseach on cancer. Schistosomes, liver fluker and Helicobacter Pylori.IARC monographs on the evalition on carcinogenic risks to human. Vo161, Lyon: IASC, 1994.
[6] Montenero AS, Mollichelli N,Zumbo F, et a1.Helicobacter pylori and atrial fibrillation:a possible pathogenic link.Heart,2005,91:960-961.
[7] ho S,Miyaji H,Azuma T,et a1.Hyperammonaemia and helicobacter pylori[J].Lancet,1995,346:124.
[8] 焦建中,赵春林,陈官培.慢性肝病中幽门螺杆菌感染的临床研究[J].中国综合临床,2003,19(1):47—48。
[9] Yamanishi S,Iizumi T'Watanad E,et a1.Implications for induction of autoimmunity via activation of B-1 ceNs by helicobacterpylofi urease.Infect Immun,2006,74:248-256。
[10] Pounder RE, Ng D. The prevalence of Helicobacter Pylori infection in different countries.science, 1995, 267:17.
[11] Guisset M,Coton T,Rey P,Debonne JM.Helicobacter pylori infection in developing countries.Med Trop(Mars),1997;57:77-82
[12] Weyermann,Maria;Adler,Guido;Brenner,Hermann;RothenbacherDietrich,The Mother as Source of Helicobacter pylori Infection,Epidemiology. 2006, 17(3):332-334
[13] Li Yy,Hu Pj,Du,GG.et al.The prevalence of Helicobacter pylori infection in P.R.China.Am J Gastroenterol,1991;86:446-449
[14] Czinn SJ. Nedrud JG. Oral immunization against Heli-cobacter pylori.Infect Immun,1991,59:2359-2363.
[15] Chen M,Lee A,Hazell S.Immunisation against gastrichelicobacter infection in a mouse/Helicobacter fel/smode1.Lancet,1992,339:1120～1121
[16] Kotloff K, Sztein M, Wasserman S, et al. Safety and immunogenicity of oral inactivated whole cell helicobacer pylori vaccine with adjuvant among volumteer with or without subclincalinfection. Infect Immun 2001,69(6):3581-3590
[17] [Suzuki H, Nomura S, Masaoka T, et al. Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther. 2004 Jul;20 Suppl 1:185-9
[18] Molinari M, Galli C, Norais N, et al. Vacuoles induced by Helicobacter pylori toxin contain both late endosomal and lysosomal markers. : J Biol Chem 1997 ,272(40): 25339-44.
[19] Tombola F,Carlesso C,Szabo I, et al.Helicobacter pylori vacuolating toxin forms anion-selective channels in planar lipidbilayers: possible implications for the mechanism of cellular vacuolation. Biophys J 1999, 76: 1401-1409.
[20] Pai R, Sasaki E,Tarnawski AS. Helicobacterpylori vacuolating cytotoxin (VacA) alters cytoskeleton-associated proteins and interferes with re-epithelialization of wounded gastric epithelial monolayers. Cell Biol Int. 2000; 24(5): 291-301.
[21] Weel JFL,Hulst RWP,Gerrits Y,et al.The interrelationship between cytotoxin-associated geneA,vaculating cytotoxin, and Helicobacter pylori related diseases. J Infect Dis,1996,173;1171-1175.
[22] 童明宏,孙晨光.幽门螺杆菌极其毒力因子和胃十二指肠疾病关系的研究.上海医学检验杂志,2000,17(2):96-99.
[23] Atanassov C, Pezennec L, d'Alayer J, et al. Novel antigens of Helicobacter pylori correspond to ulcer-related antibody pattern of sera from infected patients. J Clin Microbiol 2002 ,40(2):547-52.
[24] Ghiara P,Rossi M,Marchetti M, et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection[.Infect Immun,1997,65(12):4996-5002.
[25] Czerkinsky C, Russekk MW, Lycke, et al. Oral adminostration of a streptococal antigen coupled to cholera toxin B subunit evikes strong antibody in salivary glands and extramucosal tisses. Infect Immun, 1989,57(4):1072-1077
[26] Tamura S, Samegai Y, Kurata H, et al. Protection against Influenza virus infection by vaccine inocu lated intranasally with cholera toxin B subunit. Vaccine,1988, 6(5): 409-413
[27] Mckenzie S, Halsey J. Cholera toxin B subunit as a carrier protein to stimulated a mucosal immun response. J Immun,1984,133:1818-1824
[28] 李明峰,刘新梅,凌贞,等.幽门螺杆菌口服疫苗的研制及免疫原性研究.中华微生物学和免疫学杂志,2002,22(4)398-402
[29] Chikubo K,Isaka M,Yasuda Y et al.Recombinant cholera tixin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosallyco-adminnisterad bovine serum albumin. Vaccine, 1998; 16(1):150-155.
[30] Wu bong-ying, Russel M W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine, 1998; 16(2):286-292.
[31] F.奥斯伯 R.布伦特、R.E.金斯顿等编,颜子颖,王海林译,精编分子生物学实验指南,北京:科学出版社,1999 年, 39-40.
[32] F.奥斯伯 R.布伦特、R.E.金斯顿等编,颜子颖,王海林译,精编分子生物学实验指南,北京:科学出版社,1999 年,22-23.
[33] J.萨姆布鲁克, D.W.拉塞尔著,黄培堂等译,分子克险实验指南.[M],第 3 版,北京,科学出版社,2002,87-91
[34] J.萨姆布鲁克, D.W.拉塞尔著,黄培堂等译,分子克险实验指南.[M],第 3 版,北京,科学出版社,2002,91-98
[1] J.萨姆布鲁克, D.W.拉塞尔著,黄培堂等译,分子克险实验指南.[M],第 3 版,北京,科学出版社,2002,418-424
[2] J.萨姆布鲁克,E.F.弗里奇,T.曼尼阿蒂斯著,金冬雁,黎孟枫等译.[M]. 分子克隆实验指南,第 3 版,北京:科学出版社,2002 年,1252-1259.
[3] Gouy M, Gautier C. Codon usage in bacteria: correlation with geneexpressivity.Nucleic Acids Res. 1982, 10:7055-7074
[4] Gutman G A, Hatfield G W. Nonrandom utilization of codon pairs in Escherichia coli.Proc Natl Acad Sci USA. 1989, 86:3699-3703
[5] Cabilly S.Growth at sub-optimal temperatures allows the production of functional, antigen-binding Fab fragments in Escherichia coli.Gene. 1989 Dec 28;85(2):553-7.
[6] Fischer B,Summer I,Goodenough P.Isolation ,renaturation,and formation of disulfide bonds of eukaryotic proteins expressed in Escherichia coli as inclusion bodies.[J].Biotechnol Bioeng, 1993, 41(1): 3-13
[7] Rudolph R,Bohm G, lilie H, et al. Folding proteins. In: Creighton T E ed. Protein Function: A Practical Approach, 2nd.[J]. New York: IRL, 1997, 57-99
[8] CowleyDT, MackinRB. Expression, purification and charaterization of recombinant human proinsulin. [J].FEBS Lett, 1997, 402:124
[9] Kuruez I, Titus JA, Jost CA. Correct disulphide pairing and efficient refolding of detergent-solubilized single chain Fv proteins from bacterial inclusion bodies.[J]. Mol Immunol, 1995, 12:1443
[10] Patra AK,Mukhopadhyay R,Mukhija R,et al.Optimization of inclusion body solutilization and renaturation of recombinant human growth hormone from Escherichia coli.[J].Protein Expression Purif, 2000: 18: 182-19
[11] Creighton TE. How important is the molten globule for correct protein folding? Trends Biochem Sci, 1997, 22:6
[12] Maeda Y, Ueda T, Imoto T. Effective renaturation of denatured antibody improve its in vivo folding. [J].Protein Eng, 1995, 8:81-89
[13] Rozema D, Gellman S H. Artificial chaperone-assisted refolding of denatured- reduced lysizyme: modulation of the competition between renaturation and aggregation.[J]. Biochemistry, 1996, 35:15760-15771
[14] Sadana A.Protein refolding and inactivation during bioseparation: bioprocessing implications.[J].Biotech Bioeng, 1995, 48:481-489
[1] Sniezek PJ, Graham BC, Busch HB ,et al,Rapidly Growing Mycobacterial Infections After Pedicures,Arch dermatol 2003 May,139(5):629-634
[2] Prado, A. C., and Castillo, P. F. Lay clinics and an epidemic outbreak of mycobacterium skin and soft-tissue infection.,Plast Reconstr Surg. 2004 Feb;113(2):800-801.
[3] .Murillo J, Torres J, Bofill L, et al. Skin and wound infection by rapidly growing mycobacteria: an unexpected complication of liposuction and liposculpture. The Venezuelan Collaborative Infectious and Tropical Diseases Study Group.,Arch Dermatol. 2000 Nov;136(11):1347-1352.
[4] Villanueva A, Calderon RV, Vargas BA, et al.Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. Clin Infect Dis. 1997 Jun;24(6):1147-1153.
[5] Hofling-Lima AL, de Freitas D, Sampaio JL, et al. In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil.,Cornea. 2005 Aug;24(6):730-734.
[6] 刘军 李良成 扈庆华等,53株龟分枝杆菌脓肿亚种临床分离株的药敏试验研究.中国卫生检验杂志 2000, 10(4):407-408
[7] 杨致邦,陈清风,陈全等.龟分枝杆菌药物敏感性的及耐药性探讨,重庆医科大学学报,2001,26(3),247-249
[8] ISBN7-117-04066-1/R.4067 冯作化 医学分子生物学 人民卫生出版社
[9] Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis:1998 update. Tuber Lung Dis ,1998,79(1):3-29.
[10] Ahmad S, Mokaddas E, Fares E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolatesfrom Kuwait and Dubai. Diagn Microbiol Infect Dis,2002,44(3):245.
[11] Quan S, Venter H, Dabbs ER. Rivosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic.Antimicrob Agents Chemother,1997,41(11):2456-2460.
[12] 沙巍,翁心华,肖和平等。脓肿分支杆菌耐利福平情况及 rpoB 基因序列的研究 中华结核和呼吸杂志 2003,26(9)544-547
[13] Jamal MA, Maeda S, Nakata N,et al. Molecular basis of charithromycin-resistance in Mycobacterium avium intracellulare complex. Tuber Lung Dis. 2000;80(1):1-4..
[14] Wallace RJ jr, Meier A, brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium Chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother,1996 40(7):1676-1681.
[15] Vemulapalli RK, Cantey JR, Steed LL, et al. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection:case report and Literature review. J Infect,2001,43(3):163-168
[16] Pammananan T, Sander P, Brown BA, et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis, 1998,177(6):1573-1581.
[17] Zhao BY, Pine R, Domagala J,et al. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in hunan macrophages. Antimicrob Agents Chemother,1999,43(3):661-666.
[18] Isabelle G , Vincent J, Emmanuelle C.Correlation between Quinolone Susceptibility Patterns and Sequences in the A and B Subunits of DNA Gyrase in Mycobacteria. Antimicrob Agents Chemother. 1998 August; 42(8):2084–2088
[19] Isabelle G, Waladimir S, Emmanuelle C, et al. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum ,Microbiology, 1999; 145(9):2527-2532
1) Dea-Ayuela MA,Rama-Iniguez S,Bolas-Fernandez F.Vaccination of mice against intestinal Trichinella spiralis infections by oral administration of antigens microencapsulated in methacrilic acid copolymers.Vaccine,2006,24(15):2772-2780.
2) Hatzifoti C,Roussel Y,Harris AG,et a1.Mucosal immunization with a) a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.Helicobacter,2006,1 1(2):1 13-122.
3) Roelofs.Haarhuis K.Wu X.Gleichmann E.Oral tolerance to nickel requires CIM invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells.J Immunol,2004,173(2):1043-1050.
4) Talavera A,Ano G,Pino Y,et a1.Formulation in tablets of a cholera whole cells inactivated vaccine candidate.Vaccine,2006,24(16):338l-3387.
5) Karakasiliotis I,Paximadi E,Markoulatos P. Evolution of a rare vaccine-derived multirecombinant poliovirus.J Gen Virol,2005,86(Pt 11):3137-3142.
6) Franco MA, Angel J, Greenberg HB.Immunity and correlates of protectionfor rotavirus vaccines.Vaccine,2006,24(15):2718-2731.
7) Robert Putnak J,Coller BA,Voss G,et a1.An evaluation of dengue type-2 inactivated,recombinant subunit,and live-attenuated vaccine candidates in the rhesus macaque mode1.Vaccine,2005,23(35):4442-4452.
8) Sable SB,Verm a I,Khuller GK. Muhicomponent antitubemulous subunit vaccine based on immunodominan t antigens of Mycobacteriumtuberculosis.Vaccine 2005,23(32):4175-4184
9) Rouvio 0,Dvorkin T, Amir-Kmll H,et a1. Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of mufine cytomegalovirus in the salivary gland.Vaccine,2005,23(27):3508-3518.
10) 杨致邦,吴利先等。幽门螺杆菌 HpaA-CtxB 口服疫苗的研制及免疫原性研究. 中国免疫学杂志 2004,20(5)306-310
11) Lladser A.Parraga M,Quevedo L,et a1.Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.Immunobiology,2006,211(1-2):11-27.
12) Parida SK,Huygen K,Ryffel B,et a1. Novel Bacterial Delivery system with Attenuated Salmonella typhimurium Carrying Plasmid Encoding Mtb Antigen 85 Afor Mucosal Immunization:Establishment of Proof of Principle in TB Mouse Mode1.Ann N Y Acad Sci,2005,1056:366-378.
13) Dus Santos MJ, Carrillo C, Ardila F,et a1. Development of transgenlc alfalfa plants containing the fo t and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen.Vaccine,2005,23(15):1838-1843.
14) 14. Johnson DC, McFarland EJ, Muresan P, et a1. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborus and infants of HIV-1 infected women.J Infect Dis,2005,192(12):2129-2133.
15) Bellier B,Dalba C, Clem B,et a1. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant.Vaccine,2006,24(14):2643-2655.
16) Singh P,Destito G,Schneemann A,et a1.Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology.2006,4:2.
17) Faisant N,Akiki J,Siepmann F,et a1.Efects ofthe type of release medium on drug release from PLGA-based microparticles:Experiment and theory.Int J Pharm ,2006,314(2):189-197.
18) Mollenkopf HJ,Dietrich G,Fensterle J,et a1.Enhanced protective eficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles.Vaccine,2004,22(21-22):2690-2695.
19) Stanford M,Whittall T,Bergmeier LA,et a1.Oral tolerization with peptide
336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease.Clin Exp Immunol,2004,137(1):201-208.
20) Maier M.Seabrook TJ.Lemere CA.Medulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL),cholera toxin B subunit(CTB) and E.coli enterotoxin LT(R192G).Vaccine,2oo5,23(44):5 149-5159.
21) Helgeby A,Robson NC,Donachie AM ,et a1.The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity toincorporated antigens by specific targeting of B cells.J Immunol,2006,176(6):3697-3706.
22) Payette PJ,Ma X,Weeratna RD,et a1.Testing of CpG-optimized protein and DNA vaccines against the hepatitis B vinls in chimpanzees for immunogenicity and protection from hallenge.Intervirology,2006,49(3):144-151.